Our track record is not a good one with regard to applications...but let's set that aside for a moment.
Looking at the Therapeutics section (where Brilacidin would fall) in your link we see only a small group of companies.
Big Pharma: AstraZeneca, Genentech, Regeneron, Janssen, Grifols
BARDA CIADM Partnership Organizaitons: Emergent Biosoltuions
BARDA does not seem to be a likely pathway for us. It hands out large research dollars to large, reputable, accountable public companies and organizations.I would suspect that the financial situation, lack of a credible board of directors, lack of a robust team of senior officers, etc. all affect this application.
The people signing off on BARDA awards likely have some accountability. When they approve a grant to Regeneron or AstraZeneca they know where the money is going. They know that the research and data presented is probably credible. They know the money will be properly allocated and accounted for.
They can't cut a $10 million dollar check to every one-man penny stock company that claims they have the miracle cure. They likely get fired when those fail. This is likely why a collaboration with a reputable lab or university is required to have a real shot at grant money.
The cynical view is that BARDA is for those with lobbyists. The truth is likely a mix of both.
Hopefully we get a breakthrough award in conjunction with our collaborators at the lab.
Go IPIX!!
News 
Market Data 
Discover 
